From a clinical standpoint, miR-762 upregulation is tightly associated with the pathogenesis of gefitinib resistance, and may serve as a potent predictor of a poor response to EGFR-TKIs in NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.